Marty J
Department of Anesthesia, Bichat-Claude-Bernard Hospital, Paris, France.
Acta Anaesthesiol Scand Suppl. 1993;99:53-5. doi: 10.1111/j.1399-6576.1993.tb03826.x.
The traditional therapy of perioperative hypertension is now being challenged by the availability of new agents. Vasodilator therapy should be the first-line choice, although dihydropyridine calcium antagonists, particularly isradipine, appear to be suitable in this setting because of their pharmacological properties. Because of its ultrashort half-life, sodium nitroprusside has to be administered by continuous infusion, even for the treatment of an acute elevation of blood pressure. This is not the case with the new agents that have longer durations of action. A bolus administration is sufficient for the correction of most elevations of arterial pressure that are due to transient adrenergic activation. Continuous infusion is required only in patients who have sustained increases of systemic vascular resistance; these are usually patients who are already hypertensive.
围手术期高血压的传统治疗方法如今正受到新型药物的挑战。血管扩张剂疗法应作为一线选择,尽管二氢吡啶类钙拮抗剂,尤其是伊拉地平,因其药理特性在这种情况下似乎也适用。由于硝普钠半衰期极短,即便用于治疗血压急性升高时也必须持续输注。而新型药物作用时间更长,情况则并非如此。对于大多数因短暂性肾上腺素能激活导致的动脉压升高,单次推注给药就足以纠正。仅在系统性血管阻力持续增加的患者中才需要持续输注;这些患者通常本身就患有高血压。